DK2386310T3 - Methods of preserving organs and tissues - Google Patents

Methods of preserving organs and tissues Download PDF

Info

Publication number: DK2386310T3
Authority: DK; Denmark
Prior art keywords: phe; glu; cys; gly; ala
Prior art date: 2002-08-28

Application number

DK10191739.1T

Other languages

Danish (da)

English (en)

Inventor

Marco Cicardi

Luigi Bergamaschini

Original Assignee

Dyax Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-08-28

Filing date

2003-06-06

Publication date

2019-02-25

2003-06-06 Application filed by Dyax Corp filed Critical Dyax Corp

2019-02-25 Application granted granted Critical

2019-02-25 Publication of DK2386310T3 publication Critical patent/DK2386310T3/en

Links

238000000034 method Methods 0.000 title claims description 109
210000000056 organ Anatomy 0.000 title claims description 54
150000001413 amino acids Chemical class 0.000 claims description 186
108090000765 processed proteins & peptides Proteins 0.000 claims description 160
102000004196 processed proteins & peptides Human genes 0.000 claims description 120
229920001184 polypeptide Polymers 0.000 claims description 109
239000000203 mixture Substances 0.000 claims description 84
102000001399 Kallikrein Human genes 0.000 claims description 53
108060005987 Kallikrein Proteins 0.000 claims description 53
239000000243 solution Substances 0.000 claims description 29
210000004072 lung Anatomy 0.000 claims description 9
206010063837 Reperfusion injury Diseases 0.000 claims description 8
210000002216 heart Anatomy 0.000 claims description 7
210000003734 kidney Anatomy 0.000 claims description 7
210000004185 liver Anatomy 0.000 claims description 7
210000000496 pancreas Anatomy 0.000 claims description 7
230000002792 vascular Effects 0.000 claims description 7
230000003511 endothelial effect Effects 0.000 claims description 6
229920001612 Hydroxyethyl starch Polymers 0.000 claims description 5
229940050526 hydroxyethylstarch Drugs 0.000 claims description 5
210000000936 intestine Anatomy 0.000 claims description 5
239000000162 organ preservation solution Substances 0.000 claims description 5
238000006467 substitution reaction Methods 0.000 claims description 5
238000001356 surgical procedure Methods 0.000 claims description 4
239000003963 antioxidant agent Substances 0.000 claims description 3
JLKIGFTWXXRPMT-UHFFFAOYSA-N sulphamethoxazole Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 JLKIGFTWXXRPMT-UHFFFAOYSA-N 0.000 claims description 3
230000003078 antioxidant effect Effects 0.000 claims description 2
229940098166 bactrim Drugs 0.000 claims description 2
OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 claims 10
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims 8
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 8
RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims 8
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 6
239000002126 C01EB10 - Adenosine Substances 0.000 claims 5
229960005305 adenosine Drugs 0.000 claims 5
108010024636 Glutathione Proteins 0.000 claims 4
OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 claims 4
229960003459 allopurinol Drugs 0.000 claims 4
229960003180 glutathione Drugs 0.000 claims 4
229910052943 magnesium sulfate Inorganic materials 0.000 claims 4
235000019341 magnesium sulphate Nutrition 0.000 claims 4
239000011780 sodium chloride Substances 0.000 claims 4
102000004877 Insulin Human genes 0.000 claims 3
108090001061 Insulin Proteins 0.000 claims 3
239000007836 KH2PO4 Substances 0.000 claims 3
UBQYURCVBFRUQT-UHFFFAOYSA-N N-benzoyl-Ferrioxamine B Chemical compound CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN UBQYURCVBFRUQT-UHFFFAOYSA-N 0.000 claims 3
229960000958 deferoxamine Drugs 0.000 claims 3
229940125396 insulin Drugs 0.000 claims 3
229910000402 monopotassium phosphate Inorganic materials 0.000 claims 3
235000019796 monopotassium phosphate Nutrition 0.000 claims 3
GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 claims 3
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims 2
229930091371 Fructose Natural products 0.000 claims 2
RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims 2
239000005715 Fructose Substances 0.000 claims 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 2
239000001110 calcium chloride Substances 0.000 claims 2
235000011148 calcium chloride Nutrition 0.000 claims 2
229910001628 calcium chloride Inorganic materials 0.000 claims 2
239000008103 glucose Substances 0.000 claims 2
MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 claims 1
MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 claims 1
UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims 1
229960003957 dexamethasone Drugs 0.000 claims 1
229940099584 lactobionate Drugs 0.000 claims 1
JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 claims 1
MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 claims 1
235000001014 amino acid Nutrition 0.000 description 197
BKIFWLQFOOKUCA-DCAQKATOSA-N Met-His-Ser Chemical compound CSCC[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](CO)C(=O)O)N BKIFWLQFOOKUCA-DCAQKATOSA-N 0.000 description 65
UEHNWRNADDPYNK-DLOVCJGASA-N Phe-Cys-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CS)NC(=O)[C@H](CC1=CC=CC=C1)N UEHNWRNADDPYNK-DLOVCJGASA-N 0.000 description 65
DNAXXTQSTKOHFO-QEJZJMRPSA-N Phe-Lys-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CC1=CC=CC=C1 DNAXXTQSTKOHFO-QEJZJMRPSA-N 0.000 description 65
IDOGEHIWMJMAHT-BYPYZUCNSA-N Gly-Gly-Cys Chemical compound NCC(=O)NCC(=O)N[C@@H](CS)C(O)=O IDOGEHIWMJMAHT-BYPYZUCNSA-N 0.000 description 63
UDPSLLFHOLGXBY-FXQIFTODSA-N Cys-Glu-Glu Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O UDPSLLFHOLGXBY-FXQIFTODSA-N 0.000 description 61
LTAWNJXSRUCFAN-UNQGMJICSA-N Phe-Thr-Arg Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O LTAWNJXSRUCFAN-UNQGMJICSA-N 0.000 description 60
HUZGPXBILPMCHM-IHRRRGAJSA-N Asn-Arg-Phe Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O HUZGPXBILPMCHM-IHRRRGAJSA-N 0.000 description 57
101000975003 Homo sapiens Kallistatin Proteins 0.000 description 57
101001077723 Homo sapiens Serine protease inhibitor Kazal-type 6 Proteins 0.000 description 57
NUSWUSKZRCGFEX-FXQIFTODSA-N Glu-Glu-Cys Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CS)C(O)=O NUSWUSKZRCGFEX-FXQIFTODSA-N 0.000 description 56
102100023012 Kallistatin Human genes 0.000 description 56
KJIXWRWPOCKYLD-IHRRRGAJSA-N Lys-Lys-Met Chemical compound CSCC[C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)N KJIXWRWPOCKYLD-IHRRRGAJSA-N 0.000 description 56
108010012581 phenylalanylglutamate Proteins 0.000 description 56
108010017949 tyrosyl-glycyl-glycine Proteins 0.000 description 56
YWEHYKGJWHPGPY-XGEHTFHBSA-N Cys-Thr-Arg Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)NC(=O)[C@H](CS)N)O YWEHYKGJWHPGPY-XGEHTFHBSA-N 0.000 description 55
IDEODOAVGCMUQV-GUBZILKMSA-N Glu-Ser-Leu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O IDEODOAVGCMUQV-GUBZILKMSA-N 0.000 description 55
108010041407 alanylaspartic acid Proteins 0.000 description 51
FANQWNCPNFEPGZ-WHFBIAKZSA-N Asp-Asp-Gly Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(O)=O FANQWNCPNFEPGZ-WHFBIAKZSA-N 0.000 description 49
KMSGYZQRXPUKGI-BYPYZUCNSA-N Gly-Gly-Asn Chemical compound NCC(=O)NCC(=O)N[C@H](C(O)=O)CC(N)=O KMSGYZQRXPUKGI-BYPYZUCNSA-N 0.000 description 44
210000001519 tissue Anatomy 0.000 description 44
108010016616 cysteinylglycine Proteins 0.000 description 43
XNMYNGDKJNOKHH-BZSNNMDCSA-N Phe-Ser-Tyr Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O XNMYNGDKJNOKHH-BZSNNMDCSA-N 0.000 description 38
125000003275 alpha amino acid group Chemical group 0.000 description 34
108010065135 phenylalanyl-phenylalanyl-phenylalanine Proteins 0.000 description 34
MNBHKGYCLBUIBC-UFYCRDLUSA-N Arg-Phe-Phe Chemical compound C([C@H](NC(=O)[C@H](CCCNC(N)=N)N)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 MNBHKGYCLBUIBC-UFYCRDLUSA-N 0.000 description 31
KIEPQOIQHFKQLK-PCBIJLKTSA-N Phe-Asn-Ile Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O KIEPQOIQHFKQLK-PCBIJLKTSA-N 0.000 description 30
QSLKWWDKIXMWJV-SRVKXCTJSA-N His-Cys-Lys Chemical compound C1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCCN)C(=O)O)N QSLKWWDKIXMWJV-SRVKXCTJSA-N 0.000 description 28
OWSLLRKCHLTUND-BZSNNMDCSA-N Phe-Phe-Asn Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H](CC(=O)N)C(=O)O)N OWSLLRKCHLTUND-BZSNNMDCSA-N 0.000 description 23
108010039627 Aprotinin Proteins 0.000 description 22
210000004027 cell Anatomy 0.000 description 20
229940122920 Kallikrein inhibitor Drugs 0.000 description 19
108010084264 glycyl-glycyl-cysteine Proteins 0.000 description 19
240000004808 Saccharomyces cerevisiae Species 0.000 description 17
235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 17
239000013612 plasmid Substances 0.000 description 16
KZNQNBZMBZJQJO-UHFFFAOYSA-N N-glycyl-L-proline Natural products NCC(=O)N1CCCC1C(O)=O KZNQNBZMBZJQJO-UHFFFAOYSA-N 0.000 description 15
108020004414 DNA Proteins 0.000 description 14
HJAICMSAKODKRF-GUBZILKMSA-N Arg-Cys-Arg Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O HJAICMSAKODKRF-GUBZILKMSA-N 0.000 description 12
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
108010073025 phenylalanylphenylalanine Proteins 0.000 description 12
HGRBNYQIMKTUNT-XVYDVKMFSA-N Ala-Asn-His Chemical compound C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N HGRBNYQIMKTUNT-XVYDVKMFSA-N 0.000 description 11
241000024188 Andala Species 0.000 description 11
NPDLYUOYAGBHFB-WDSKDSINSA-N Asn-Arg Chemical compound NC(=O)C[C@H](N)C(=O)N[C@H](C(O)=O)CCCN=C(N)N NPDLYUOYAGBHFB-WDSKDSINSA-N 0.000 description 11
KGIHMGPYGXBYJJ-SRVKXCTJSA-N Cys-Lys-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CS KGIHMGPYGXBYJJ-SRVKXCTJSA-N 0.000 description 11
WIDZHJTYKYBLSR-DCAQKATOSA-N Leu-Glu-Glu Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O WIDZHJTYKYBLSR-DCAQKATOSA-N 0.000 description 11
CEGVMWAVGBRVFS-XGEHTFHBSA-N Met-Cys-Thr Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CS)C(=O)N[C@@H]([C@@H](C)O)C(O)=O CEGVMWAVGBRVFS-XGEHTFHBSA-N 0.000 description 11
JWQWPTLEOFNCGX-AVGNSLFASA-N Phe-Glu-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 JWQWPTLEOFNCGX-AVGNSLFASA-N 0.000 description 11
LOVIQNMIPQVIGT-BVSLBCMMSA-N Arg-Trp-Phe Chemical compound C([C@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCCN=C(N)N)N)C(O)=O)C1=CC=CC=C1 LOVIQNMIPQVIGT-BVSLBCMMSA-N 0.000 description 10
FFMIYIMKQIMDPK-BQBZGAKWSA-N Asn-His Chemical compound NC(=O)C[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CN=CN1 FFMIYIMKQIMDPK-BQBZGAKWSA-N 0.000 description 10
108091026890 Coding region Proteins 0.000 description 10
NUZHSNLQJDYSRW-BZSNNMDCSA-N Pro-Arg-Trp Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O NUZHSNLQJDYSRW-BZSNNMDCSA-N 0.000 description 10
108020001507 fusion proteins Proteins 0.000 description 10
239000002773 nucleotide Substances 0.000 description 10
125000003729 nucleotide group Chemical group 0.000 description 10
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
JQLQUPIYYJXZLJ-ZEWNOJEFSA-N Phe-Ile-Tyr Chemical compound C([C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=CC=C1 JQLQUPIYYJXZLJ-ZEWNOJEFSA-N 0.000 description 9
HIINQLBHPIQYHN-JTQLQIEISA-N Tyr-Gly-Gly Chemical compound OC(=O)CNC(=O)CNC(=O)[C@@H](N)CC1=CC=C(O)C=C1 HIINQLBHPIQYHN-JTQLQIEISA-N 0.000 description 9
239000013604 expression vector Substances 0.000 description 9
102000037865 fusion proteins Human genes 0.000 description 9
102100036826 Aldehyde oxidase Human genes 0.000 description 8
101000928314 Homo sapiens Aldehyde oxidase Proteins 0.000 description 8
VGTJSEYTVMAASM-RPTUDFQQSA-N Phe-Thr-Tyr Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O VGTJSEYTVMAASM-RPTUDFQQSA-N 0.000 description 8
OLTFZQIYCNOBLI-DCAQKATOSA-N Pro-Cys-Lys Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCCN)C(=O)O OLTFZQIYCNOBLI-DCAQKATOSA-N 0.000 description 8
229960004405 aprotinin Drugs 0.000 description 8
ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 8
WQVFQXXBNHHPLX-ZKWXMUAHSA-N Ala-Ala-His Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](Cc1cnc[nH]1)C(O)=O WQVFQXXBNHHPLX-ZKWXMUAHSA-N 0.000 description 7
UXUSHQYYQCZWET-WDSKDSINSA-N Cys-Glu-Gly Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(O)=O UXUSHQYYQCZWET-WDSKDSINSA-N 0.000 description 7
UHVIQGKBMXEVGN-WDSKDSINSA-N Glu-Gly-Asn Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(O)=O UHVIQGKBMXEVGN-WDSKDSINSA-N 0.000 description 7
FKJQNJCQTKUBCD-XPUUQOCRSA-N Gly-Ala-His Chemical compound NCC(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CNC=N1)C(=O)O FKJQNJCQTKUBCD-XPUUQOCRSA-N 0.000 description 7
VEPIBPGLTLPBDW-URLPEUOOSA-N Ile-Phe-Thr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)N VEPIBPGLTLPBDW-URLPEUOOSA-N 0.000 description 7
108010076504 Protein Sorting Signals Proteins 0.000 description 7
238000010367 cloning Methods 0.000 description 7
235000018417 cysteine Nutrition 0.000 description 7
238000002054 transplantation Methods 0.000 description 7
101150069554 HIS4 gene Proteins 0.000 description 6
VKOAHIRLIUESLU-ULQDDVLXSA-N Leu-Arg-Phe Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O VKOAHIRLIUESLU-ULQDDVLXSA-N 0.000 description 6
108091028043 Nucleic acid sequence Proteins 0.000 description 6
KDIIENQUNVNWHR-JYJNAYRXSA-N Pro-Arg-Phe Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O KDIIENQUNVNWHR-JYJNAYRXSA-N 0.000 description 6
AIZVVCMAFRREQS-GUBZILKMSA-N Pro-Cys-Arg Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O AIZVVCMAFRREQS-GUBZILKMSA-N 0.000 description 6
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
102100030951 Tissue factor pathway inhibitor Human genes 0.000 description 6
230000004913 activation Effects 0.000 description 6
230000000694 effects Effects 0.000 description 6
230000002401 inhibitory effect Effects 0.000 description 6
108010013555 lipoprotein-associated coagulation inhibitor Proteins 0.000 description 6
108010064235 lysylglycine Proteins 0.000 description 6
238000004519 manufacturing process Methods 0.000 description 6
238000004321 preservation Methods 0.000 description 6
KMGOBAQSCKTBGD-DLOVCJGASA-N Ala-His-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](C)N)CC1=CN=CN1 KMGOBAQSCKTBGD-DLOVCJGASA-N 0.000 description 5
HUUOZYZWNCXTFK-INTQDDNPSA-N Ala-His-Pro Chemical compound C[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N2CCC[C@@H]2C(=O)O)N HUUOZYZWNCXTFK-INTQDDNPSA-N 0.000 description 5
VGRHZPNRCLAHQA-IMJSIDKUSA-N Asp-Asn Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CC(N)=O)C(O)=O VGRHZPNRCLAHQA-IMJSIDKUSA-N 0.000 description 5
241000235058 Komagataella pastoris Species 0.000 description 5
102000012479 Serine Proteases Human genes 0.000 description 5
108010022999 Serine Proteases Proteins 0.000 description 5
230000015572 biosynthetic process Effects 0.000 description 5
210000004369 blood Anatomy 0.000 description 5
239000008280 blood Substances 0.000 description 5
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 5
239000013613 expression plasmid Substances 0.000 description 5
238000004191 hydrophobic interaction chromatography Methods 0.000 description 5
238000003752 polymerase chain reaction Methods 0.000 description 5
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 5
108010004914 prolylarginine Proteins 0.000 description 5
238000003860 storage Methods 0.000 description 5
230000035899 viability Effects 0.000 description 5
NHLAEBFGWPXFGI-WHFBIAKZSA-N Ala-Gly-Asn Chemical compound C[C@@H](C(=O)NCC(=O)N[C@@H](CC(=O)N)C(=O)O)N NHLAEBFGWPXFGI-WHFBIAKZSA-N 0.000 description 4
OMMIEVATLAGRCK-BYPYZUCNSA-N Asp-Gly-Gly Chemical compound OC(=O)C[C@H](N)C(=O)NCC(=O)NCC(O)=O OMMIEVATLAGRCK-BYPYZUCNSA-N 0.000 description 4
KGHLGJAXYSVNJP-WHFBIAKZSA-N Asp-Ser-Gly Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CO)C(=O)NCC(O)=O KGHLGJAXYSVNJP-WHFBIAKZSA-N 0.000 description 4
XWKPSMRPIKKDDU-RCOVLWMOSA-N Asp-Val-Gly Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(O)=O XWKPSMRPIKKDDU-RCOVLWMOSA-N 0.000 description 4
BUXAPSQPMALTOY-WHFBIAKZSA-N Cys-Glu Chemical compound SC[C@H](N)C(=O)N[C@H](C(O)=O)CCC(O)=O BUXAPSQPMALTOY-WHFBIAKZSA-N 0.000 description 4
BXNGIHFNNNSEOS-UWVGGRQHSA-N Phe-Asn Chemical compound NC(=O)C[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 BXNGIHFNNNSEOS-UWVGGRQHSA-N 0.000 description 4
108090000113 Plasma Kallikrein Proteins 0.000 description 4
BLPYXIXXCFVIIF-FXQIFTODSA-N Ser-Cys-Arg Chemical compound C(C[C@@H](C(=O)O)NC(=O)[C@H](CS)NC(=O)[C@H](CO)N)CN=C(N)N BLPYXIXXCFVIIF-FXQIFTODSA-N 0.000 description 4
230000006378 damage Effects 0.000 description 4
238000000855 fermentation Methods 0.000 description 4
230000004151 fermentation Effects 0.000 description 4
230000004927 fusion Effects 0.000 description 4
239000003112 inhibitor Substances 0.000 description 4
230000005764 inhibitory process Effects 0.000 description 4
239000000082 organ preservation Substances 0.000 description 4
239000003761 preservation solution Substances 0.000 description 4
239000003755 preservative agent Substances 0.000 description 4
230000002335 preservative effect Effects 0.000 description 4
238000000746 purification Methods 0.000 description 4
239000000523 sample Substances 0.000 description 4
239000000758 substrate Substances 0.000 description 4
230000001225 therapeutic effect Effects 0.000 description 4
LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 4
210000005253 yeast cell Anatomy 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
HOVPGJUNRLMIOZ-CIUDSAMLSA-N Ala-Ser-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](C)N HOVPGJUNRLMIOZ-CIUDSAMLSA-N 0.000 description 3
POTCZYQVVNXUIG-BQBZGAKWSA-N Asp-Gly-Pro Chemical compound OC(=O)C[C@H](N)C(=O)NCC(=O)N1CCC[C@H]1C(O)=O POTCZYQVVNXUIG-BQBZGAKWSA-N 0.000 description 3
101100505161 Caenorhabditis elegans mel-32 gene Proteins 0.000 description 3
SZQCDCKIGWQAQN-FXQIFTODSA-N Cys-Arg-Ala Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(O)=O SZQCDCKIGWQAQN-FXQIFTODSA-N 0.000 description 3
108010088842 Fibrinolysin Proteins 0.000 description 3
PRTZQMBYUZFSFA-XEGUGMAKSA-N Ile-Tyr-Gly Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)NCC(=O)O)N PRTZQMBYUZFSFA-XEGUGMAKSA-N 0.000 description 3
229940127379 Kallikrein Inhibitors Drugs 0.000 description 3
FADYJNXDPBKVCA-UHFFFAOYSA-N L-Phenylalanyl-L-lysin Natural products NCCCCC(C(O)=O)NC(=O)C(N)CC1=CC=CC=C1 FADYJNXDPBKVCA-UHFFFAOYSA-N 0.000 description 3
MPGHETGWWWUHPY-CIUDSAMLSA-N Lys-Ala-Asp Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCCN MPGHETGWWWUHPY-CIUDSAMLSA-N 0.000 description 3
102000035195 Peptidases Human genes 0.000 description 3
108091005804 Peptidases Proteins 0.000 description 3
239000004365 Protease Substances 0.000 description 3
KCGIREHVWRXNDH-GARJFASQSA-N Ser-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CO)N KCGIREHVWRXNDH-GARJFASQSA-N 0.000 description 3
108010005233 alanylglutamic acid Proteins 0.000 description 3
108010069205 aspartyl-phenylalanine Proteins 0.000 description 3
238000004587 chromatography analysis Methods 0.000 description 3
230000015271 coagulation Effects 0.000 description 3
238000005345 coagulation Methods 0.000 description 3
108010025306 histidylleucine Proteins 0.000 description 3
108010085325 histidylproline Proteins 0.000 description 3
108010057821 leucylproline Proteins 0.000 description 3
150000007523 nucleic acids Chemical class 0.000 description 3
230000037361 pathway Effects 0.000 description 3
238000010647 peptide synthesis reaction Methods 0.000 description 3
229940012957 plasmin Drugs 0.000 description 3
229920005644 polyethylene terephthalate glycol copolymer Polymers 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
235000018102 proteins Nutrition 0.000 description 3
108090000623 proteins and genes Proteins 0.000 description 3
102000004169 proteins and genes Human genes 0.000 description 3
238000003259 recombinant expression Methods 0.000 description 3
238000011218 seed culture Methods 0.000 description 3
239000007790 solid phase Substances 0.000 description 3
238000003786 synthesis reaction Methods 0.000 description 3
230000008718 systemic inflammatory response Effects 0.000 description 3
FJVAQLJNTSUQPY-CIUDSAMLSA-N Ala-Ala-Lys Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CCCCN FJVAQLJNTSUQPY-CIUDSAMLSA-N 0.000 description 2
SVHRPCMZTWZROG-DCAQKATOSA-N Arg-Cys-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CS)NC(=O)[C@H](CCCN=C(N)N)N SVHRPCMZTWZROG-DCAQKATOSA-N 0.000 description 2
OVQJAKFLFTZDNC-GUBZILKMSA-N Arg-Pro-Asp Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(O)=O)C(O)=O OVQJAKFLFTZDNC-GUBZILKMSA-N 0.000 description 2
WQSCVMQDZYTFQU-FXQIFTODSA-N Asn-Cys-Arg Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O WQSCVMQDZYTFQU-FXQIFTODSA-N 0.000 description 2
HYQYLOSCICEYTR-YUMQZZPRSA-N Asn-Gly-Leu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(O)=O HYQYLOSCICEYTR-YUMQZZPRSA-N 0.000 description 2
IKLAUGBIDCDFOY-SRVKXCTJSA-N Asn-His-Leu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(C)C)C(O)=O IKLAUGBIDCDFOY-SRVKXCTJSA-N 0.000 description 2
XDGBFDYXZCMYEX-NUMRIWBASA-N Asp-Glu-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(=O)O)N)O XDGBFDYXZCMYEX-NUMRIWBASA-N 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
108020004705 Codon Proteins 0.000 description 2
ZOLXQKZHYOHHMD-DLOVCJGASA-N Cys-Ala-Phe Chemical compound C[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)NC(=O)[C@H](CS)N ZOLXQKZHYOHHMD-DLOVCJGASA-N 0.000 description 2
241000588724 Escherichia coli Species 0.000 description 2
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
HUWSBFYAGXCXKC-CIUDSAMLSA-N Glu-Ala-Met Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCSC)C(O)=O HUWSBFYAGXCXKC-CIUDSAMLSA-N 0.000 description 2
OAGVHWYIBZMWLA-YFKPBYRVSA-N Glu-Gly-Gly Chemical compound OC(=O)CC[C@H](N)C(=O)NCC(=O)NCC(O)=O OAGVHWYIBZMWLA-YFKPBYRVSA-N 0.000 description 2
DCBSZJJHOTXMHY-DCAQKATOSA-N Glu-Pro-Pro Chemical compound OC(=O)CC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 DCBSZJJHOTXMHY-DCAQKATOSA-N 0.000 description 2
FUESBOMYALLFNI-VKHMYHEASA-N Gly-Asn Chemical compound NCC(=O)N[C@H](C(O)=O)CC(N)=O FUESBOMYALLFNI-VKHMYHEASA-N 0.000 description 2
XXGQRGQPGFYECI-WDSKDSINSA-N Gly-Cys-Glu Chemical compound NCC(=O)N[C@@H](CS)C(=O)N[C@H](C(O)=O)CCC(O)=O XXGQRGQPGFYECI-WDSKDSINSA-N 0.000 description 2
QQJMARNOLHSJCQ-DCAQKATOSA-N His-Cys-Arg Chemical compound C1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N QQJMARNOLHSJCQ-DCAQKATOSA-N 0.000 description 2
IAYPZSHNZQHQNO-KKUMJFAQSA-N His-Ser-Phe Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC2=CN=CN2)N IAYPZSHNZQHQNO-KKUMJFAQSA-N 0.000 description 2
101001091365 Homo sapiens Plasma kallikrein Proteins 0.000 description 2
101000653189 Homo sapiens Tissue factor pathway inhibitor Proteins 0.000 description 2
102000002397 Kinins Human genes 0.000 description 2
108010093008 Kinins Proteins 0.000 description 2
LXUJDHOKVUYHRC-KKUMJFAQSA-N Phe-Cys-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CS)NC(=O)[C@H](CC1=CC=CC=C1)N LXUJDHOKVUYHRC-KKUMJFAQSA-N 0.000 description 2
YMIZSYUAZJSOFL-SRVKXCTJSA-N Phe-Ser-Asn Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(O)=O YMIZSYUAZJSOFL-SRVKXCTJSA-N 0.000 description 2
102000003827 Plasma Kallikrein Human genes 0.000 description 2
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
ZIFYDQAFEMIZII-GUBZILKMSA-N Ser-Leu-Glu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O ZIFYDQAFEMIZII-GUBZILKMSA-N 0.000 description 2
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
GLQFKOVWXPPFTP-VEVYYDQMSA-N Thr-Arg-Asp Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(O)=O GLQFKOVWXPPFTP-VEVYYDQMSA-N 0.000 description 2
VBMOVTMNHWPZJR-SUSMZKCASA-N Thr-Thr-Glu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(O)=O VBMOVTMNHWPZJR-SUSMZKCASA-N 0.000 description 2
ZZDYJFVIKVSUFA-WLTAIBSBSA-N Tyr-Thr-Gly Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(O)=O ZZDYJFVIKVSUFA-WLTAIBSBSA-N 0.000 description 2
108700042768 University of Wisconsin-lactobionate solution Proteins 0.000 description 2
PVPAOIGJYHVWBT-KKHAAJSZSA-N Val-Asn-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](C(C)C)N)O PVPAOIGJYHVWBT-KKHAAJSZSA-N 0.000 description 2
ZHQWPWQNVRCXAX-XQQFMLRXSA-N Val-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](C(C)C)N ZHQWPWQNVRCXAX-XQQFMLRXSA-N 0.000 description 2
108010087049 alanyl-alanyl-prolyl-valine Proteins 0.000 description 2
KOSRFJWDECSPRO-UHFFFAOYSA-N alpha-L-glutamyl-L-glutamic acid Natural products OC(=O)CCC(N)C(=O)NC(CCC(O)=O)C(O)=O KOSRFJWDECSPRO-UHFFFAOYSA-N 0.000 description 2
BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 2
229910052921 ammonium sulfate Inorganic materials 0.000 description 2
235000011130 ammonium sulphate Nutrition 0.000 description 2
108010027371 asparaginyl-leucyl-prolyl-arginine Proteins 0.000 description 2
238000003556 assay Methods 0.000 description 2
230000008901 benefit Effects 0.000 description 2
230000017531 blood circulation Effects 0.000 description 2
210000000988 bone and bone Anatomy 0.000 description 2
229910052799 carbon Inorganic materials 0.000 description 2
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
238000005277 cation exchange chromatography Methods 0.000 description 2
-1 coagulation Proteins 0.000 description 2
210000004351 coronary vessel Anatomy 0.000 description 2
125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
150000001945 cysteines Chemical group 0.000 description 2
230000029087 digestion Effects 0.000 description 2
239000003814 drug Substances 0.000 description 2
238000011156 evaluation Methods 0.000 description 2
238000001914 filtration Methods 0.000 description 2
108010063718 gamma-glutamylaspartic acid Proteins 0.000 description 2
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
230000006801 homologous recombination Effects 0.000 description 2
238000002744 homologous recombination Methods 0.000 description 2
208000028867 ischemia Diseases 0.000 description 2
108010077158 leucinyl-arginyl-tryptophan Proteins 0.000 description 2
108010009298 lysylglutamic acid Proteins 0.000 description 2
230000001404 mediated effect Effects 0.000 description 2
238000000386 microscopy Methods 0.000 description 2
230000004048 modification Effects 0.000 description 2
238000012986 modification Methods 0.000 description 2
108020004707 nucleic acids Proteins 0.000 description 2
102000039446 nucleic acids Human genes 0.000 description 2
238000004806 packaging method and process Methods 0.000 description 2
238000002823 phage display Methods 0.000 description 2
229910000160 potassium phosphate Inorganic materials 0.000 description 2
235000011009 potassium phosphates Nutrition 0.000 description 2
230000008569 process Effects 0.000 description 2
239000000047 product Substances 0.000 description 2
230000000717 retained effect Effects 0.000 description 2
230000028327 secretion Effects 0.000 description 2
239000012679 serum free medium Substances 0.000 description 2
239000001632 sodium acetate Substances 0.000 description 2
235000017281 sodium acetate Nutrition 0.000 description 2
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
238000010561 standard procedure Methods 0.000 description 2
238000003756 stirring Methods 0.000 description 2
239000000126 substance Substances 0.000 description 2
239000006228 supernatant Substances 0.000 description 2
238000012360 testing method Methods 0.000 description 2
238000012546 transfer Methods 0.000 description 2
238000005406 washing Methods 0.000 description 2
108010027345 wheylin-1 peptide Proteins 0.000 description 2
125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
JMTMSDXUXJISAY-UHFFFAOYSA-N 2H-benzotriazol-4-ol Chemical compound OC1=CC=CC2=C1N=NN2 JMTMSDXUXJISAY-UHFFFAOYSA-N 0.000 description 1
AUUIARVPJHGTSA-UHFFFAOYSA-N 3-(aminomethyl)chromen-2-one Chemical compound C1=CC=C2OC(=O)C(CN)=CC2=C1 AUUIARVPJHGTSA-UHFFFAOYSA-N 0.000 description 1
YYSWCHMLFJLLBJ-ZLUOBGJFSA-N Ala-Ala-Ser Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O YYSWCHMLFJLLBJ-ZLUOBGJFSA-N 0.000 description 1
SKHCUBQVZJHOFM-NAKRPEOUSA-N Ala-Arg-Ile Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O SKHCUBQVZJHOFM-NAKRPEOUSA-N 0.000 description 1
XZWXFWBHYRFLEF-FSPLSTOPSA-N Ala-His Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CN=CN1 XZWXFWBHYRFLEF-FSPLSTOPSA-N 0.000 description 1
XCZXVTHYGSMQGH-NAKRPEOUSA-N Ala-Ile-Met Chemical compound C[C@H]([NH3+])C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCSC)C([O-])=O XCZXVTHYGSMQGH-NAKRPEOUSA-N 0.000 description 1
OYJCVIGKMXUVKB-GARJFASQSA-N Ala-Leu-Pro Chemical compound C[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@@H]1C(=O)O)N OYJCVIGKMXUVKB-GARJFASQSA-N 0.000 description 1
QUIGLPSHIFPEOV-CIUDSAMLSA-N Ala-Lys-Ala Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O QUIGLPSHIFPEOV-CIUDSAMLSA-N 0.000 description 1
MAEQBGQTDWDSJQ-LSJOCFKGSA-N Ala-Met-His Chemical compound C[C@@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N MAEQBGQTDWDSJQ-LSJOCFKGSA-N 0.000 description 1
IPWKGIFRRBGCJO-IMJSIDKUSA-N Ala-Ser Chemical compound C[C@H]([NH3+])C(=O)N[C@@H](CO)C([O-])=O IPWKGIFRRBGCJO-IMJSIDKUSA-N 0.000 description 1
DYXOFPBJBAHWFY-JBDRJPRFSA-N Ala-Ser-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](C)N DYXOFPBJBAHWFY-JBDRJPRFSA-N 0.000 description 1
108700028369 Alleles Proteins 0.000 description 1
239000005995 Aluminium silicate Substances 0.000 description 1
VBFJESQBIWCWRL-DCAQKATOSA-N Arg-Ala-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCNC(N)=N VBFJESQBIWCWRL-DCAQKATOSA-N 0.000 description 1
USNSOPDIZILSJP-FXQIFTODSA-N Arg-Asn-Asn Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O USNSOPDIZILSJP-FXQIFTODSA-N 0.000 description 1
HPKSHFSEXICTLI-CIUDSAMLSA-N Arg-Glu-Ala Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(O)=O HPKSHFSEXICTLI-CIUDSAMLSA-N 0.000 description 1
LXMKTIZAGIBQRX-HRCADAONSA-N Arg-Phe-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CCCN=C(N)N)N)C(=O)O LXMKTIZAGIBQRX-HRCADAONSA-N 0.000 description 1
HRCIIMCTUIAKQB-XGEHTFHBSA-N Arg-Thr-Cys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N)O HRCIIMCTUIAKQB-XGEHTFHBSA-N 0.000 description 1
LFWOQHSQNCKXRU-UFYCRDLUSA-N Arg-Tyr-Phe Chemical compound C([C@H](NC(=O)[C@H](CCCN=C(N)N)N)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=C(O)C=C1 LFWOQHSQNCKXRU-UFYCRDLUSA-N 0.000 description 1
RVHGJNGNKGDCPX-KKUMJFAQSA-N Asn-Phe-Lys Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC(=O)N)N RVHGJNGNKGDCPX-KKUMJFAQSA-N 0.000 description 1
UXHYOWXTJLBEPG-GSSVUCPTSA-N Asn-Thr-Thr Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O UXHYOWXTJLBEPG-GSSVUCPTSA-N 0.000 description 1
WXASLRQUSYWVNE-FXQIFTODSA-N Asp-Cys-Met Chemical compound CSCC[C@@H](C(=O)O)NC(=O)[C@H](CS)NC(=O)[C@H](CC(=O)O)N WXASLRQUSYWVNE-FXQIFTODSA-N 0.000 description 1
DWOGMPWRQQWPPF-GUBZILKMSA-N Asp-Leu-Glu Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O DWOGMPWRQQWPPF-GUBZILKMSA-N 0.000 description 1
WOPJVEMFXYHZEE-SRVKXCTJSA-N Asp-Phe-Asp Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(O)=O)C(O)=O WOPJVEMFXYHZEE-SRVKXCTJSA-N 0.000 description 1
XWKBWZXGNXTDKY-ZKWXMUAHSA-N Asp-Val-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CC(O)=O XWKBWZXGNXTDKY-ZKWXMUAHSA-N 0.000 description 1
102000015081 Blood Coagulation Factors Human genes 0.000 description 1
108010039209 Blood Coagulation Factors Proteins 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
DZLQXIFVQFTFJY-BYPYZUCNSA-N Cys-Gly-Gly Chemical compound SC[C@H](N)C(=O)NCC(=O)NCC(O)=O DZLQXIFVQFTFJY-BYPYZUCNSA-N 0.000 description 1
108010062466 Enzyme Precursors Proteins 0.000 description 1
102000010911 Enzyme Precursors Human genes 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
NCWOMXABNYEPLY-NRPADANISA-N Glu-Ala-Val Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(O)=O NCWOMXABNYEPLY-NRPADANISA-N 0.000 description 1
ISXJHXGYMJKXOI-GUBZILKMSA-N Glu-Cys-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CS)NC(=O)[C@@H](N)CCC(O)=O ISXJHXGYMJKXOI-GUBZILKMSA-N 0.000 description 1
SJPMNHCEWPTRBR-BQBZGAKWSA-N Glu-Glu-Gly Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(O)=O SJPMNHCEWPTRBR-BQBZGAKWSA-N 0.000 description 1
YLJHCWNDBKKOEB-IHRRRGAJSA-N Glu-Glu-Phe Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O YLJHCWNDBKKOEB-IHRRRGAJSA-N 0.000 description 1
MTAOBYXRYJZRGQ-WDSKDSINSA-N Glu-Gly-Asp Chemical compound OC(=O)CC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O MTAOBYXRYJZRGQ-WDSKDSINSA-N 0.000 description 1
HILMIYALTUQTRC-XVKPBYJWSA-N Glu-Gly-Val Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](C(C)C)C(O)=O HILMIYALTUQTRC-XVKPBYJWSA-N 0.000 description 1
VSVZIEVNUYDAFR-YUMQZZPRSA-N Gly-Ala-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)CN VSVZIEVNUYDAFR-YUMQZZPRSA-N 0.000 description 1
DUYYPIRFTLOAJQ-YUMQZZPRSA-N Gly-Asn-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)CN DUYYPIRFTLOAJQ-YUMQZZPRSA-N 0.000 description 1
JVWPPCWUDRJGAE-YUMQZZPRSA-N Gly-Asn-Leu Chemical compound [H]NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(O)=O JVWPPCWUDRJGAE-YUMQZZPRSA-N 0.000 description 1
CEXINUGNTZFNRY-BYPYZUCNSA-N Gly-Cys-Gly Chemical compound [NH3+]CC(=O)N[C@@H](CS)C(=O)NCC([O-])=O CEXINUGNTZFNRY-BYPYZUCNSA-N 0.000 description 1
CCQOOWAONKGYKQ-BYPYZUCNSA-N Gly-Gly-Ala Chemical compound OC(=O)[C@H](C)NC(=O)CNC(=O)CN CCQOOWAONKGYKQ-BYPYZUCNSA-N 0.000 description 1
YIFUFYZELCMPJP-YUMQZZPRSA-N Gly-Leu-Cys Chemical compound NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(O)=O YIFUFYZELCMPJP-YUMQZZPRSA-N 0.000 description 1
DNAZKGFYFRGZIH-QWRGUYRKSA-N Gly-Tyr-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CC1=CC=C(O)C=C1 DNAZKGFYFRGZIH-QWRGUYRKSA-N 0.000 description 1
SOYCWSKCUVDLMC-AVGNSLFASA-N His-Pro-Arg Chemical compound N[C@@H](Cc1cnc[nH]1)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCCNC(=N)N)C(=O)O SOYCWSKCUVDLMC-AVGNSLFASA-N 0.000 description 1
CWJQMCPYXNVMBS-STECZYCISA-N Ile-Arg-Tyr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)N CWJQMCPYXNVMBS-STECZYCISA-N 0.000 description 1
UAQSZXGJGLHMNV-XEGUGMAKSA-N Ile-Gly-Tyr Chemical compound CC[C@H](C)[C@@H](C(=O)NCC(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)N UAQSZXGJGLHMNV-XEGUGMAKSA-N 0.000 description 1
ZUPJCJINYQISSN-XUXIUFHCSA-N Ile-Met-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)O)N ZUPJCJINYQISSN-XUXIUFHCSA-N 0.000 description 1
IITVUURPOYGCTD-NAKRPEOUSA-N Ile-Pro-Ala Chemical compound CC[C@H](C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(O)=O IITVUURPOYGCTD-NAKRPEOUSA-N 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
241001506991 Komagataella phaffii GS115 Species 0.000 description 1
RCFDOSNHHZGBOY-UHFFFAOYSA-N L-isoleucyl-L-alanine Natural products CCC(C)C(N)C(=O)NC(C)C(O)=O RCFDOSNHHZGBOY-UHFFFAOYSA-N 0.000 description 1
KFKWRHQBZQICHA-STQMWFEESA-N L-leucyl-L-phenylalanine Natural products CC(C)C[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 KFKWRHQBZQICHA-STQMWFEESA-N 0.000 description 1
XYUBOFCTGPZFSA-WDSOQIARSA-N Leu-Arg-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(C)C)C(O)=O)=CNC2=C1 XYUBOFCTGPZFSA-WDSOQIARSA-N 0.000 description 1
HQUXQAMSWFIRET-AVGNSLFASA-N Leu-Glu-Lys Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(O)=O)CCCCN HQUXQAMSWFIRET-AVGNSLFASA-N 0.000 description 1
ZDBMWELMUCLUPL-QEJZJMRPSA-N Leu-Phe-Ala Chemical compound CC(C)C[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](C)C(O)=O)CC1=CC=CC=C1 ZDBMWELMUCLUPL-QEJZJMRPSA-N 0.000 description 1
XFIHDSBIPWEYJJ-YUMQZZPRSA-N Lys-Ala-Gly Chemical compound OC(=O)CNC(=O)[C@H](C)NC(=O)[C@@H](N)CCCCN XFIHDSBIPWEYJJ-YUMQZZPRSA-N 0.000 description 1
ALSRJRIWBNENFY-DCAQKATOSA-N Lys-Arg-Asn Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(O)=O ALSRJRIWBNENFY-DCAQKATOSA-N 0.000 description 1
JGAMUXDWYSXYLM-SRVKXCTJSA-N Lys-Arg-Glu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(O)=O JGAMUXDWYSXYLM-SRVKXCTJSA-N 0.000 description 1
WALVCOOOKULCQM-ULQDDVLXSA-N Lys-Arg-Phe Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O WALVCOOOKULCQM-ULQDDVLXSA-N 0.000 description 1
TYEJPFJNAHIKRT-DCAQKATOSA-N Lys-Met-Cys Chemical compound CSCC[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CCCCN)N TYEJPFJNAHIKRT-DCAQKATOSA-N 0.000 description 1
OBVHKUFUDCPZDW-JYJNAYRXSA-N Met-Arg-Phe Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 OBVHKUFUDCPZDW-JYJNAYRXSA-N 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
108010079364 N-glycylalanine Proteins 0.000 description 1
108091034117 Oligonucleotide Proteins 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
238000002944 PCR assay Methods 0.000 description 1
108010067372 Pancreatic elastase Proteins 0.000 description 1
102000016387 Pancreatic elastase Human genes 0.000 description 1
206010033645 Pancreatitis Diseases 0.000 description 1
108010088535 Pep-1 peptide Proteins 0.000 description 1
102000003992 Peroxidases Human genes 0.000 description 1
WKTSCAXSYITIJJ-PCBIJLKTSA-N Phe-Ile-Asn Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(O)=O WKTSCAXSYITIJJ-PCBIJLKTSA-N 0.000 description 1
SCKXGHWQPPURGT-KKUMJFAQSA-N Phe-Lys-Ser Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O SCKXGHWQPPURGT-KKUMJFAQSA-N 0.000 description 1
GMWNQSGWWGKTSF-LFSVMHDDSA-N Phe-Thr-Ala Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O GMWNQSGWWGKTSF-LFSVMHDDSA-N 0.000 description 1
GTMSCDVFQLNEOY-BZSNNMDCSA-N Phe-Tyr-Asn Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CC(=O)N)C(=O)O)N GTMSCDVFQLNEOY-BZSNNMDCSA-N 0.000 description 1
GAMLAXHLYGLQBJ-UFYCRDLUSA-N Phe-Val-Tyr Chemical compound N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)O)CC1=CC=C(C=C1)O)C(C)C)CC1=CC=CC=C1 GAMLAXHLYGLQBJ-UFYCRDLUSA-N 0.000 description 1
IWNOFCGBMSFTBC-CIUDSAMLSA-N Pro-Ala-Glu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(O)=O IWNOFCGBMSFTBC-CIUDSAMLSA-N 0.000 description 1
ITUDDXVFGFEKPD-NAKRPEOUSA-N Pro-Ser-Ile Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O ITUDDXVFGFEKPD-NAKRPEOUSA-N 0.000 description 1
SRTCFKGBYBZRHA-ACZMJKKPSA-N Ser-Ala-Glu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(O)=O SRTCFKGBYBZRHA-ACZMJKKPSA-N 0.000 description 1
BGOWRLSWJCVYAQ-CIUDSAMLSA-N Ser-Asp-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O BGOWRLSWJCVYAQ-CIUDSAMLSA-N 0.000 description 1
LWMQRHDTXHQQOV-MXAVVETBSA-N Ser-Ile-Phe Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O LWMQRHDTXHQQOV-MXAVVETBSA-N 0.000 description 1
HJAXVYLCKDPPDF-SRVKXCTJSA-N Ser-Phe-Cys Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CO)N HJAXVYLCKDPPDF-SRVKXCTJSA-N 0.000 description 1
HHJFMHQYEAAOBM-ZLUOBGJFSA-N Ser-Ser-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(O)=O HHJFMHQYEAAOBM-ZLUOBGJFSA-N 0.000 description 1
SQHKXWODKJDZRC-LKXGYXEUSA-N Ser-Thr-Asn Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(O)=O SQHKXWODKJDZRC-LKXGYXEUSA-N 0.000 description 1
XSLXHSYIVPGEER-KZVJFYERSA-N Thr-Ala-Val Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(O)=O XSLXHSYIVPGEER-KZVJFYERSA-N 0.000 description 1
HYLXOQURIOCKIH-VQVTYTSYSA-N Thr-Arg Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@H](C(O)=O)CCCNC(N)=N HYLXOQURIOCKIH-VQVTYTSYSA-N 0.000 description 1
NWECYMJLJGCBOD-UNQGMJICSA-N Thr-Phe-Val Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C(C)C)C(O)=O NWECYMJLJGCBOD-UNQGMJICSA-N 0.000 description 1
NHQVWACSJZJCGJ-FLBSBUHZSA-N Thr-Thr-Ile Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O NHQVWACSJZJCGJ-FLBSBUHZSA-N 0.000 description 1
108090000190 Thrombin Proteins 0.000 description 1
102000003978 Tissue Plasminogen Activator Human genes 0.000 description 1
108090000373 Tissue Plasminogen Activator Proteins 0.000 description 1
BOMYCJXTWRMKJA-RNXOBYDBSA-N Trp-Phe-Phe Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)O)NC(=O)[C@H](CC3=CNC4=CC=CC=C43)N BOMYCJXTWRMKJA-RNXOBYDBSA-N 0.000 description 1
206010064390 Tumour invasion Diseases 0.000 description 1
DKKHULUSOSWGHS-UWJYBYFXSA-N Tyr-Asn-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC1=CC=C(C=C1)O)N DKKHULUSOSWGHS-UWJYBYFXSA-N 0.000 description 1
102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
ZZGPVSZDZQRJQY-ULQDDVLXSA-N Val-Leu-Phe Chemical compound CC(C)C[C@H](NC(=O)[C@@H](N)C(C)C)C(=O)N[C@@H](Cc1ccccc1)C(O)=O ZZGPVSZDZQRJQY-ULQDDVLXSA-N 0.000 description 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
150000008065 acid anhydrides Chemical class 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
108091006088 activator proteins Proteins 0.000 description 1
108010008685 alanyl-glutamyl-aspartic acid Proteins 0.000 description 1
108010047495 alanylglycine Proteins 0.000 description 1
108010070944 alanylhistidine Proteins 0.000 description 1
235000012211 aluminium silicate Nutrition 0.000 description 1
125000000539 amino acid group Chemical group 0.000 description 1
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
229960000723 ampicillin Drugs 0.000 description 1
210000000709 aorta Anatomy 0.000 description 1
ZPNFWUPYTFPOJU-MPSLMFKFSA-N aprotinin Chemical compound CC[C@H](C)[C@@H]1NC(=O)[C@@H](CCCNC(N)=N)NC(=O)[C@@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@@H]2CSSC[C@H]3NC(=O)CNC(=O)CNC(=O)[C@H](Cc4ccc(O)cc4)NC(=O)[C@H](NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CSSC[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](Cc4ccccc4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC3=O)C(=O)N[C@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](CSSC[C@@H](NC(=O)[C@H](Cc3ccccc3)NC(=O)[C@@H](CC(O)=O)NC(=O)[C@H]3CCCN3C(=O)[C@H](N)CCCNC(N)=N)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N3CCC[C@@H]3C(=O)N3CCC[C@H]3C(=O)N[C@H](Cc3ccc(O)cc3)C(=O)N[C@H]([C@H](C)O)C(=O)NCC(=O)N3CCC[C@H]3C(=O)N2)C(=O)NCC(=O)NCC(=O)N[C@H](C)C(O)=O)NC(=O)[C@@H](CC(C)C)NC(=O)CNC(=O)[C@@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](Cc2ccc(O)cc2)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H](Cc2ccc(O)cc2)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](NC1=O)[C@H](C)CC)[C@@H](C)O)C(C)C ZPNFWUPYTFPOJU-MPSLMFKFSA-N 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
239000002585 base Substances 0.000 description 1
230000008236 biological pathway Effects 0.000 description 1
101150049515 bla gene Proteins 0.000 description 1
239000003114 blood coagulation factor Substances 0.000 description 1
239000000872 buffer Substances 0.000 description 1
239000008364 bulk solution Substances 0.000 description 1
230000009400 cancer invasion Effects 0.000 description 1
150000001718 carbodiimides Chemical class 0.000 description 1
238000007675 cardiac surgery Methods 0.000 description 1
229940100084 cardioplegia solution Drugs 0.000 description 1
230000002612 cardiopulmonary effect Effects 0.000 description 1
239000000969 carrier Substances 0.000 description 1
238000005341 cation exchange Methods 0.000 description 1
230000003833 cell viability Effects 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
230000004154 complement system Effects 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
238000010276 construction Methods 0.000 description 1
230000008878 coupling Effects 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
239000012228 culture supernatant Substances 0.000 description 1
229960000633 dextran sulfate Drugs 0.000 description 1
238000010586 diagram Methods 0.000 description 1
FSXRLASFHBWESK-UHFFFAOYSA-N dipeptide phenylalanyl-tyrosine Natural products C=1C=C(O)C=CC=1CC(C(O)=O)NC(=O)C(N)CC1=CC=CC=C1 FSXRLASFHBWESK-UHFFFAOYSA-N 0.000 description 1
229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
239000012154 double-distilled water Substances 0.000 description 1
239000003596 drug target Substances 0.000 description 1
210000002889 endothelial cell Anatomy 0.000 description 1
229940088598 enzyme Drugs 0.000 description 1
150000002148 esters Chemical group 0.000 description 1
230000005284 excitation Effects 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
239000000284 extract Substances 0.000 description 1
230000020764 fibrinolysis Effects 0.000 description 1
238000009472 formulation Methods 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
239000011521 glass Substances 0.000 description 1
108010055341 glutamyl-glutamic acid Proteins 0.000 description 1
108010049041 glutamylalanine Proteins 0.000 description 1
VPZXBVLAVMBEQI-UHFFFAOYSA-N glycyl-DL-alpha-alanine Natural products OC(=O)C(C)NC(=O)CN VPZXBVLAVMBEQI-UHFFFAOYSA-N 0.000 description 1
108010000434 glycyl-alanyl-leucine Proteins 0.000 description 1
108010020688 glycylhistidine Proteins 0.000 description 1
108010077515 glycylproline Proteins 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
208000014674 injury Diseases 0.000 description 1
238000011081 inoculation Methods 0.000 description 1
239000002054 inoculum Substances 0.000 description 1
230000000968 intestinal effect Effects 0.000 description 1
230000000302 ischemic effect Effects 0.000 description 1
NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
238000003367 kinetic assay Methods 0.000 description 1
108010044056 leucyl-phenylalanine Proteins 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
108010054155 lysyllysine Proteins 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
230000002107 myocardial effect Effects 0.000 description 1
210000000440 neutrophil Anatomy 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
239000002245 particle Substances 0.000 description 1
125000000538 pentafluorophenyl group Chemical group FC1=C(F)C(F)=C(*)C(F)=C1F 0.000 description 1
239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
230000010412 perfusion Effects 0.000 description 1
108040007629 peroxidase activity proteins Proteins 0.000 description 1
239000012071 phase Substances 0.000 description 1
230000004983 pleiotropic effect Effects 0.000 description 1
238000012545 processing Methods 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
108010031719 prolyl-serine Proteins 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
125000006239 protecting group Chemical group 0.000 description 1
235000004252 protein component Nutrition 0.000 description 1
230000004853 protein function Effects 0.000 description 1
230000002797 proteolythic effect Effects 0.000 description 1
239000008213 purified water Substances 0.000 description 1
239000011535 reaction buffer Substances 0.000 description 1
238000010188 recombinant method Methods 0.000 description 1
238000011084 recovery Methods 0.000 description 1
238000012429 release testing Methods 0.000 description 1
239000011347 resin Substances 0.000 description 1
229920005989 resin Polymers 0.000 description 1
108091008146 restriction endonucleases Proteins 0.000 description 1
230000007017 scission Effects 0.000 description 1
238000012216 screening Methods 0.000 description 1
230000003248 secreting effect Effects 0.000 description 1
238000002864 sequence alignment Methods 0.000 description 1
238000012163 sequencing technique Methods 0.000 description 1
239000011734 sodium Substances 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
210000004872 soft tissue Anatomy 0.000 description 1
229960005404 sulfamethoxazole Drugs 0.000 description 1
125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
229960004072 thrombin Drugs 0.000 description 1
229960000187 tissue plasminogen activator Drugs 0.000 description 1
230000009466 transformation Effects 0.000 description 1
230000009261 transgenic effect Effects 0.000 description 1
229940108519 trasylol Drugs 0.000 description 1
230000008733 trauma Effects 0.000 description 1
IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical group COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 description 1
229960001082 trimethoprim Drugs 0.000 description 1
HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
229940038773 trisodium citrate Drugs 0.000 description 1
238000000108 ultra-filtration Methods 0.000 description 1
238000013060 ultrafiltration and diafiltration Methods 0.000 description 1
241000701447 unidentified baculovirus Species 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/10—Preservation of living parts
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/10—Preservation of living parts
- A01N1/12—Chemical aspects of preservation
- A01N1/122—Preservation or perfusion media
- A01N1/126—Physiologically active agents, e.g. antioxidants or nutrients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

Life Sciences & Earth Sciences (AREA)
Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Wood Science & Technology (AREA)
Dentistry (AREA)
Environmental Sciences (AREA)
Zoology (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Agricultural Chemicals And Associated Chemicals (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

DK10191739.1T 2002-08-28 2003-06-06 Methods of preserving organs and tissues DK2386310T3 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US40700402P	2002-08-28	2002-08-28
EP03791557A EP1542710B1 (en)	2002-08-28	2003-06-06	Methods for preserving organs and tissues

Publications (1)

Publication Number	Publication Date
DK2386310T3 true DK2386310T3 (en)	2019-02-25

Family

ID=31978403

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DK10191739.1T DK2386310T3 (en)	2002-08-28	2003-06-06	Methods of preserving organs and tissues
DK03791557.6T DK1542710T3 (da)	2002-08-28	2003-06-06	Fremgangsmåde til konservering af organer og væv

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
DK03791557.6T DK1542710T3 (da)	2002-08-28	2003-06-06	Fremgangsmåde til konservering af organer og væv

Country Status (14)

Country	Link
US (3)	US7166576B2 (es)
EP (2)	EP2386310B1 (es)
JP (2)	JP2005537006A (es)
AU (2)	AU2003243413B2 (es)
CA (1)	CA2496789C (es)
CY (1)	CY1121194T1 (es)
DK (2)	DK2386310T3 (es)
ES (2)	ES2395014T3 (es)
HK (1)	HK1076039A1 (es)
HU (1)	HUE042899T2 (es)
PT (1)	PT2386310T (es)
SI (1)	SI2386310T1 (es)
TR (1)	TR201900937T4 (es)
WO (1)	WO2004019968A1 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1489097B1 (en) *	1994-01-11	2011-10-19	Dyax Corporation	Inhibitors of human plasmin derived from kunitz domains and nucleic acids encoding the same
US6057287A (en)	1994-01-11	2000-05-02	Dyax Corp.	Kallikrein-binding "Kunitz domain" proteins and analogues thereof
US20050026132A1 (en) *	2000-11-03	2005-02-03	University Of Rochester	Warm intermittent perfusion
US20050222023A1 (en) *	2002-02-07	2005-10-06	Hans-Peter Hauser	Albumin-fused kunitz domain peptides
US7153829B2 (en) *	2002-06-07	2006-12-26	Dyax Corp.	Kallikrein-inhibitor therapies
DK2298278T3 (en)	2002-06-07	2016-02-01	Dyax Corp	Prevention and reduction of blood loss and inflammatory response
EP2386310B1 (en) *	2002-08-28	2018-11-07	Dyax Corp.	Methods for preserving organs and tissues
US6989369B2 (en) *	2003-02-07	2006-01-24	Dyax Corp.	Kunitz domain peptides
CA3050564A1 (en) *	2003-08-29	2005-03-10	Dyax Corp.	Poly-pegylated protease inhibitors
US7235530B2 (en) *	2004-09-27	2007-06-26	Dyax Corporation	Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
AU2005318464B2 (en)	2004-12-23	2012-02-23	Csl Behring Gmbh	Prevention of thrombus formation and/or stabilization
US20060160062A1 (en) *	2005-01-14	2006-07-20	Young Lindon H	Perfusion and/or preservation solution for organs
WO2006138562A2 (en) *	2005-06-17	2006-12-28	Mannkind Corporation	Epitope analogues
JP2009529542A (ja) *	2006-03-10	2009-08-20	ダイアックスコーポレーション	エカランチドに関する配合物
LT1854477T (lt) *	2006-03-16	2016-12-12	Dyax Corp.	Peptidai, slopinantys plazmos kalikreiną, skirti naudoti oftalmologinių sutrikimų gydymui
CA2696208A1 (en) *	2007-08-21	2009-02-26	Genzyme Corporation	Treatment with kallikrein inhibitors
AU2008288772A1 (en) *	2007-08-23	2009-02-26	Genzyme Corporation	Treatment with kallikrein inhibitors
US20090263780A1 (en) *	2008-04-17	2009-10-22	Yanming Wang	Organ preservation fluid
JP2013516389A (ja)	2009-01-06	2013-05-13	ダイアックスコーポレーション	カリクレイン阻害剤による粘膜炎治療
US8465471B2 (en)	2009-08-05	2013-06-18	Rocin Laboratories, Inc.	Endoscopically-guided electro-cauterizing power-assisted fat aspiration system for aspirating visceral fat tissue within the abdomen of a patient
US20110213336A1 (en)	2009-08-05	2011-09-01	Cucin Robert L	Method of and apparatus for sampling, processing and collecting tissue and reinjecting the same into human patients
US8348929B2 (en)	2009-08-05	2013-01-08	Rocin Laboratories, Inc.	Endoscopically-guided tissue aspiration system for safely removing fat tissue from a patient
SI2521568T1 (sl)	2010-01-06	2019-01-31	Dyax Corp.	Proteini, ki vežejo plazemski kalikrein
KR102502293B1 (ko)	2011-01-06	2023-02-21	다케다 파머수티컬 컴패니 리미티드	혈장 칼리크레인 결합 단백질
KR20230109785A (ko)	2014-03-27	2023-07-20	다케다 파머수티컬 컴패니 리미티드	당뇨병성 황반 부종의 치료를 위한 조성물 및 방법
WO2017100679A1 (en)	2015-12-11	2017-06-15	Dyax Corp.	Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack

Family Cites Families (116)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AT275583B (de)	1964-03-04	1969-10-27	Plasser Bahnbaumasch Franz	Profilfreie Maschine zum Reinigen des Eisenbahnbettungsschotters
BR6915369D0 (pt) *	1969-02-27	1973-03-13	Bayer Ag	Emprego de inibidores biologicos de proteases para conservacao de orgaos tecidos e alimentos
US3691016A (en)	1970-04-17	1972-09-12	Monsanto Co	Process for the preparation of insoluble enzymes
CA1023287A (en)	1972-12-08	1977-12-27	Boehringer Mannheim G.M.B.H.	Process for the preparation of carrier-bound proteins
US4179337A (en)	1973-07-20	1979-12-18	Davis Frank F	Non-immunogenic polypeptides
DE2619246A1 (de)	1976-04-30	1977-11-10	Bayer Ag	Desamino-derivate des kallikrein- trypsin-inhibitors, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel
US4195128A (en)	1976-05-03	1980-03-25	Bayer Aktiengesellschaft	Polymeric carrier bound ligands
DE2654124A1 (de)	1976-11-29	1978-06-01	Bayer Ag	Derivate des trypsin-kallikrein-inhibitors aus rinderorganen (bpti) mit proteasenhemmwirkung und antiphlogistischer wirkung, ihre herstellung und ihre verwendung als arzneimittel
US4330440A (en)	1977-02-08	1982-05-18	Development Finance Corporation Of New Zealand	Activated matrix and method of activation
CA1093991A (en)	1977-02-17	1981-01-20	Hideo Hirohara	Enzyme immobilization with pullulan gel
US4229537A (en)	1978-02-09	1980-10-21	New York University	Preparation of trichloro-s-triazine activated supports for coupling ligands
AT359653B (de)	1979-02-15	1980-11-25	Immuno Ag	Verfahren zur herstellung eines gewebekleb- stoffes
US5179017A (en)	1980-02-25	1993-01-12	The Trustees Of Columbia University In The City Of New York	Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en)	1980-02-25	1987-01-06	The Trustees Of Columbia University In The City Of New York	Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en)	1980-02-25	1983-08-16	The Trustees Of Columbia University	Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
AU560584B2 (en)	1983-07-28	1987-04-09	Bayer Aktiengesellschaft	Homologues of aprotinin
US4657893A (en)	1984-05-09	1987-04-14	Syntex (U.S.A.) Inc.	4H-3,1-benzoxazin-4-ones and related compounds and use as enzyme inhibitors
US4845242A (en)	1987-04-28	1989-07-04	Georgia Tech Research Corporation	Isocoumarins with basic substituents as serine proteases inhibitors, anticoagulants and anti-inflammatory agents
US4609725A (en)	1984-10-09	1986-09-02	Merck & Co., Inc.	Cardiac atrial peptides
US5444156A (en)	1985-07-12	1995-08-22	Temple University-Of The Commonwealth System Of Higher Education	Monoclonal antibodies to human plasma prekallikrein
US4879283A (en)	1985-10-03	1989-11-07	Wisconsin Alumni Research Foundation	Solution for the preservation of organs
US4798824A (en)	1985-10-03	1989-01-17	Wisconsin Alumni Research Foundation	Perfusate for the preservation of organs
EP0255011A3 (en)	1986-07-29	1988-11-23	Miles Inc.	Human inter-alpha-trypsin inhibitor gene
US5260203A (en)	1986-09-02	1993-11-09	Enzon, Inc.	Single polypeptide chain binding molecules
US4946778A (en)	1987-09-21	1990-08-07	Genex Corporation	Single polypeptide chain binding molecules
US4881175A (en)	1986-09-02	1989-11-14	Genex Corporation	Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
EP0285123A3 (en)	1987-04-03	1989-02-01	Stabra AG	A method for complete mutagenesis of nucleic acids
GB2208511A (en)	1987-08-07	1989-04-05	Bayer Ag	Variants of bovine pancreatic trypsin inhibitor produced by recombinant dna technology
DK225488D0 (da)	1988-04-26	1988-04-26	Novo Industri As	Polypeptid
US5223409A (en)	1988-09-02	1993-06-29	Protein Engineering Corp.	Directed evolution of novel binding proteins
US7078383B2 (en)	1988-09-02	2006-07-18	Dyax Corp.	ITI-D1 Kunitz domain mutants as HNE inhibitors
US5372933A (en)	1988-10-03	1994-12-13	The Scripps Research Institute	Polypeptides that mimic receptor-induced binding sites, and methods of using same
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
ES2066033T3 (es)	1989-05-13	1995-03-01	Bayer Ag	Inhibidores de las proteinasas, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
US5145771A (en)	1990-04-12	1992-09-08	The University Of North Carolina At Chapel Hill	Rinse solution for organs and tissues
IL99585A0 (en)	1990-10-01	1992-08-18	Novo Nordisk As	Aprotinin analogues,their production and pharmaceutical compositions containing them
EP0486001A1 (en)	1990-11-13	1992-05-20	Mochida Pharmaceutical Co., Ltd.	Recombinant urinary trypsin inhibitor fragments and drug composition
US6407213B1 (en)	1991-06-14	2002-06-18	Genentech, Inc.	Method for making humanized antibodies
WO1993009233A2 (en)	1991-10-31	1993-05-13	The Salk Institute Biotechnology/Industrial Associates Inc.	Recombinant amyloid precursor protein inhibitor domain and treatment of various disease states
IL104326A0 (en)	1992-01-07	1993-05-13	Novo Nordisk As	Variant of human kunitz-type protease inhibitor
IL104324A0 (en) *	1992-01-07	1993-05-13	Novo Nordisk As	Variant of human kunitz-type protease inhibitor
IL104325A (en)	1992-01-07	2000-10-31	Novo Nordisk As	Variants of human kunitz-type protease inhibitor domain II of tissue factor pathway inhibitor (TFPI) pharmaceutical compositions containing them a DNA construct encoding them their expression vectors a cell containing said DNA constructs and methods for the production of all the above
RU2025973C1 (ru)	1992-02-10	1995-01-09	Научно-производственное предприятие "Биофарм"	Раствор для консервации живых органов
US5552267A (en)	1992-04-03	1996-09-03	The Trustees Of Columbia University In The City Of New York	Solution for prolonged organ preservation
US5370989A (en)	1992-04-03	1994-12-06	The Trustees Of Columbia University In The City Of New York	Solution for prolonged organ preservation
DE69314032T2 (de)	1992-06-26	1998-04-23	Torii Pharmaceutical Co Ltd	Flüssigkeit zur konservierung von organen
CA2139945A1 (en)	1992-07-13	1994-01-20	Ignace Lasters	Bovine pancreatic trypsin inhibitor derived inhibitors of factor xa
US5436153A (en)	1992-12-02	1995-07-25	Sprecher; Cindy A.	Human amyloid protein precursor homolog and Kunitz-type inhibitor
WO1994012637A2 (en)	1992-12-02	1994-06-09	Zymogenetics, Inc.	Novel human amyloid protein precursor homologue and kunitz-type inhibitors
US5426224A (en)	1993-03-18	1995-06-20	The University Of North Carolina At Chapel Hill	Mammalian DNA topoisomerase II inhibitor and method
US5405742A (en)	1993-07-16	1995-04-11	Cyromedical Sciences, Inc.	Solutions for tissue preservation and bloodless surgery and methods using same
CA2170030A1 (en)	1993-09-14	1995-03-23	Robert A. Lazarus	Pharmaceutical compositions containing ecotin and homologs thereof
US5951974A (en)	1993-11-10	1999-09-14	Enzon, Inc.	Interferon polymer conjugates
US5759548A (en)	1993-11-30	1998-06-02	Lxr Biotechnology Inc.	Compositions which inhibit apoptosis, methods of purifying the compositions and uses thereof
US5827690A (en)	1993-12-20	1998-10-27	Genzyme Transgenics Corporatiion	Transgenic production of antibodies in milk
US6057287A (en)	1994-01-11	2000-05-02	Dyax Corp.	Kallikrein-binding "Kunitz domain" proteins and analogues thereof
DK0739355T3 (da)	1994-01-11	2005-01-24	Dyax Corp	Kallikrein-inhiberende "Kunitz-domæne"-proteiner og analoger deraf
EP1489097B1 (en)	1994-01-11	2011-10-19	Dyax Corporation	Inhibitors of human plasmin derived from kunitz domains and nucleic acids encoding the same
US5795954A (en)	1994-03-04	1998-08-18	Genentech, Inc.	Factor VIIa inhibitors from Kunitz domain proteins
JPH09512021A (ja) *	1994-04-19	1997-12-02	ザユニバーシティオブカンサス	Ｉｃａｍ−１／ｌｆａ−１短鎖ペプチドおよび該ペプチドの使用方法
AU711405B2 (en)	1994-10-18	1999-10-14	Dendreon Corporation	Nematode-extracted serine protease inhibitors and anticoagulant proteins
US6159938A (en) *	1994-11-21	2000-12-12	Cortech, Inc.	Serine protease inhibitors comprising α-keto heterocycles
EP0715850B1 (en)	1994-12-07	2004-11-10	Ajinomoto Co., Inc.	Use of proline and/or derivatives as an antihepatitis agent
AU4467396A (en)	1994-12-12	1996-07-10	Omeros Medical Systems, Inc.	Irrigation solution and method for inhibition of pain, inflammation and spasm
MX9703988A (es)	1994-12-12	1998-02-28	Omeros Med Sys Inc	SOLUCIaN Y MÉTODO DE IRRIGACIaN PARA LA INHIBICIaN DEL DOLOR, LA INFLAMACIaN Y ES ESPASMO.
DK0813525T3 (da)	1995-03-10	2004-02-16	Berlex Lab	Benzamidinderivater, deres fremstilling og anvendelse som antikoagulanter
ZA963619B (en)	1995-05-08	1996-11-22	Scios Inc	Protease inhibitor peptides
US5780265A (en)	1995-06-05	1998-07-14	Genentech, Inc.	Kunitz type plasma kallikrein inhibitors
US5786328A (en)	1995-06-05	1998-07-28	Genentech, Inc.	Use of kunitz type plasma kallikrein inhibitors
US6126933A (en)	1995-06-27	2000-10-03	Genetics Institute	Methods of treating inflammatory bowel diseases by administering IL-11
WO1997009989A1 (en)	1995-09-14	1997-03-20	Lxr Biotechnology Inc.	Compositions with anti-apoptotic activity, containing a mixture of phospholipids
US5736364A (en)	1995-12-04	1998-04-07	Genentech, Inc.	Factor viia inhibitors
US6013763A (en)	1996-06-04	2000-01-11	Genentech, Inc.	Peptide variants of protein A
US5869637A (en)	1996-07-22	1999-02-09	Incyte Pharmaceuticals, Inc.	Human Kallikrein
US6255455B1 (en)	1996-10-11	2001-07-03	The Trustees Of The University Of Pennsylvania	Rh(D)-binding proteins and magnetically activated cell sorting method for production thereof
US5962300A (en)	1997-03-26	1999-10-05	Incyte Pharmaceuticals, Inc.	Human kallikrein
JP2002512624A (ja)	1997-05-21	2002-04-23	バイオベーションリミテッド	非免疫原性タンパク質の製造方法
AU7808198A (en) *	1997-06-03	1998-12-21	Biocryst Pharmaceuticals, Inc.	Novel compounds useful in the complement, coagulat and kallikrein pathways and method for their preparation
US6087473A (en)	1999-05-26	2000-07-11	Zymogenetics, Inc.	Kunitz domain polypeptide and materials and methods for making it
WO1999063090A2 (en)	1998-06-03	1999-12-09	Scios, Inc.	Protease inhibitor peptides
CA2342072C (en) *	1998-09-03	2005-01-11	Zymogenetics, Inc.	Kunitz domain polypeptide zkun6
US7067144B2 (en)	1998-10-20	2006-06-27	Omeros Corporation	Compositions and methods for systemic inhibition of cartilage degradation
CN1202128C (zh)	1998-12-08	2005-05-18	拜奥威神有限公司	修饰蛋白的免疫原性
US6180607B1 (en)	1999-08-05	2001-01-30	Christopher Davies	Protein having proteinase inhibitor activity
CN102766210B (zh)	1999-08-24	2015-07-08	E.R.施贵宝&圣斯有限责任公司	人ctla-4抗体及其应用
GB9930882D0 (en)	1999-12-30	2000-02-23	Nps Allelix Corp	GLP-2 formulations
WO2001079442A2 (en)	2000-04-12	2001-10-25	Human Genome Sciences, Inc.	Albumin fusion proteins
WO2002061131A2 (en)	2000-12-04	2002-08-08	Bristol-Myers Squibb Company	Human single nucleotide polymorphisms
EP1389044A4 (en)	2001-04-18	2006-07-05	Merck & Co Inc	PPAR-ALPHA-GAMMA AGONISTS OR LIGANDS FOR THE TREATMENT OF INFLAMMATIONS
EP1406652A2 (en)	2001-07-10	2004-04-14	Omnio AB	Novel drug targets for arthritis
EP1572930A4 (en) *	2002-02-07	2008-07-09	Novozymes Delta Ltd	KUNITZ DOMAIN PEPTIDES FUSED WITH ALBUMIN
US20050222023A1 (en) *	2002-02-07	2005-10-06	Hans-Peter Hauser	Albumin-fused kunitz domain peptides
DK2298278T3 (en) *	2002-06-07	2016-02-01	Dyax Corp	Prevention and reduction of blood loss and inflammatory response
US7153829B2 (en)	2002-06-07	2006-12-26	Dyax Corp.	Kallikrein-inhibitor therapies
EP2386310B1 (en)	2002-08-28	2018-11-07	Dyax Corp.	Methods for preserving organs and tissues
US20040224886A1 (en)	2003-01-08	2004-11-11	Chiron Corporation	Stabilized compositions comprising tissue factor pathway inhibitor protein or tissue factor pathway inhibitor variant proteins
DE602004015725D1 (de)	2003-01-08	2008-09-25	Novartis Vaccines & Diagnostic	Stabilisierte lyophilisierte zubereitungen mit gewebefaktor-inhibitor (tfpi) oder varianten des gewebefaktor-inhibitors
US6989369B2 (en)	2003-02-07	2006-01-24	Dyax Corp.	Kunitz domain peptides
CA3050564A1 (en)	2003-08-29	2005-03-10	Dyax Corp.	Poly-pegylated protease inhibitors
US8114123B2 (en)	2003-09-19	2012-02-14	St. Jude Medical, Inc.	Apparatus and methods for tissue gathering and securing
US7268109B2 (en)	2003-10-02	2007-09-11	Elan Pharmaceuticals, Inc.	Method for reducing pain
WO2005075665A2 (en)	2004-02-03	2005-08-18	Bayer Healthcare Ag	Diagnostics and therapeutics for diseases associated with plasma kallikrein (klkb1)
US7235530B2 (en)	2004-09-27	2007-06-26	Dyax Corporation	Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
AU2005318464B2 (en)	2004-12-23	2012-02-23	Csl Behring Gmbh	Prevention of thrombus formation and/or stabilization
US20060183771A1 (en)	2005-02-17	2006-08-17	Seiffert Dietmar A	Novel combination of selective factor VIIa and/or factor XIa inhibitors and selective plasma kallikrein inhibitors
DE602006020123D1 (de)	2005-05-04	2011-03-31	Zealand Pharma As	Glucagon-like-peptide-2- (glp-2-) analoga
US20070079096A1 (en)	2005-09-30	2007-04-05	Chih-Wei Chen	Data storage unit access authorization table automatic rebuilding method and system
WO2007079096A2 (en)	2005-12-29	2007-07-12	Dyax Corp.	Protease inhibition
US7276480B1 (en)	2005-12-30	2007-10-02	Dyax Corp.	Prevention and reduction of blood loss
JP2009529542A (ja)	2006-03-10	2009-08-20	ダイアックスコーポレーション	エカランチドに関する配合物
JP5322935B2 (ja)	2006-07-31	2013-10-23	アクティベサイトファーマシューティカルズインコーポレイティッド	血漿カリクレインの阻害薬
WO2008060764A2 (en)	2006-10-05	2008-05-22	Drugtech Corporation	Topical therapies for oral mucositis and other conditions
CA2696208A1 (en)	2007-08-21	2009-02-26	Genzyme Corporation	Treatment with kallikrein inhibitors
AU2008288772A1 (en)	2007-08-23	2009-02-26	Genzyme Corporation	Treatment with kallikrein inhibitors
JP2011511647A (ja)	2008-02-13	2011-04-14	ダイアックスコーポレイション	特異的結合対を作製するための改善された方法
JP2013516389A (ja)	2009-01-06	2013-05-13	ダイアックスコーポレーション	カリクレイン阻害剤による粘膜炎治療

2003
- 2003-06-06 EP EP10191739.1A patent/EP2386310B1/en not_active Expired - Lifetime
- 2003-06-06 DK DK10191739.1T patent/DK2386310T3/en active
- 2003-06-06 SI SI200332589T patent/SI2386310T1/sl unknown
- 2003-06-06 ES ES03791557T patent/ES2395014T3/es not_active Expired - Lifetime
- 2003-06-06 US US10/456,981 patent/US7166576B2/en not_active Expired - Lifetime
- 2003-06-06 EP EP03791557A patent/EP1542710B1/en not_active Expired - Lifetime
- 2003-06-06 CA CA2496789A patent/CA2496789C/en not_active Expired - Lifetime
- 2003-06-06 AU AU2003243413A patent/AU2003243413B2/en not_active Expired
- 2003-06-06 PT PT10191739T patent/PT2386310T/pt unknown
- 2003-06-06 JP JP2004532576A patent/JP2005537006A/ja active Pending
- 2003-06-06 ES ES10191739T patent/ES2709103T3/es not_active Expired - Lifetime
- 2003-06-06 HU HUE10191739A patent/HUE042899T2/hu unknown
- 2003-06-06 WO PCT/US2003/017802 patent/WO2004019968A1/en active Application Filing
- 2003-06-06 DK DK03791557.6T patent/DK1542710T3/da active
- 2003-06-06 TR TR2019/00937T patent/TR201900937T4/tr unknown
2005
- 2005-09-20 HK HK05108207.7A patent/HK1076039A1/xx not_active IP Right Cessation
2007
- 2007-01-09 US US11/621,246 patent/US7718617B2/en not_active Expired - Lifetime
2009
- 2009-06-03 AU AU2009202214A patent/AU2009202214A1/en not_active Abandoned
2010
- 2010-03-19 US US12/727,637 patent/US8748368B2/en not_active Expired - Lifetime
- 2010-11-02 JP JP2010246452A patent/JP5465648B2/ja not_active Expired - Lifetime
2019
- 2019-01-28 CY CY20191100116T patent/CY1121194T1/el unknown

Also Published As

Publication number	Publication date
WO2004019968A1 (en)	2004-03-11
EP1542710B1 (en)	2012-09-26
ES2395014T3 (es)	2013-02-07
US8748368B2 (en)	2014-06-10
US20110008762A1 (en)	2011-01-13
EP2386310A3 (en)	2012-06-13
US7718617B2 (en)	2010-05-18
JP5465648B2 (ja)	2014-04-09
US20040053206A1 (en)	2004-03-18
US7166576B2 (en)	2007-01-23
EP2386310B1 (en)	2018-11-07
JP2011078417A (ja)	2011-04-21
CA2496789C (en)	2013-12-17
EP1542710A4 (en)	2007-11-28
AU2003243413B2 (en)	2009-07-09
EP2386310A2 (en)	2011-11-16
ES2709103T3 (es)	2019-04-15
CA2496789A1 (en)	2004-03-11
CY1121194T1 (el)	2020-05-29
HK1076039A1 (en)	2006-01-06
AU2003243413A1 (en)	2004-03-19
SI2386310T1 (sl)	2019-03-29
AU2009202214A1 (en)	2009-06-25
JP2005537006A (ja)	2005-12-08
US20080050716A1 (en)	2008-02-28
TR201900937T4 (tr)	2019-02-21
PT2386310T (pt)	2019-02-05
HUE042899T2 (hu)	2019-07-29
EP1542710A1 (en)	2005-06-22
DK1542710T3 (da)	2012-10-15

Publication	Publication Date	Title
DK2386310T3 (en)	2019-02-25	Methods of preserving organs and tissues
US10245307B2 (en)	2019-04-02	Prevention and reduction of blood loss
US7276480B1 (en)	2007-10-02	Prevention and reduction of blood loss
AU2012216529B2 (en)	2014-12-11	Methods for preserving organs and tissues